Loading organizations...
NMT Capital operates as a globally oriented private equity firm, managing investment funds in Europe and the US. It specializes in enhancing portfolio company value through strategic guidance, capital introductions, and active team development. The firm focuses investments within the medical technology and life science sectors.
The firm evolved from Nexus Medical Partners, co-founded in 2004 by Edwin Snape and John F. Rousseau, Jr. Snape brings over 35 years in company formation and healthcare investment, notably founding The Liposome Company. Rousseau offers more than 30 years in investment management and operations, guiding companies through growth stages.
NMT Capital serves investors seeking returns from high-potential ventures, concurrently supporting early to growth-stage businesses in its specialized fields. The firm’s vision involves identifying and nurturing companies with significant exit potential, pursuing public listings or strategic acquisitions, ultimately driving innovation and sustainable growth in medical technology and life sciences.
NMT Capital has 1 tracked investment across 1 company. The latest tracked deal is $23.0M Series B in Proterra in November 2012.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 21, 2012 | Proterra | $23.0M Series B | Rajiv Ghatalia | 88 Green Ventures, GM Ventures, Kleiner Perkins, Mitsui & CO. Global Investment, Vision Ridge Partners |
